Анти-В клеточная терапия синдрома и болезни Шёгрена

1. <div><p>Васильев В.И., Симонова М.В., Сафонова Т.Н. Болезнь Шёгрена. В кн. Насонова В.А., Бунчук Н.В. (ред.), Ревматические болезни, М., Медицина; 1997, 196-210.</p><p>Васильев В.И., Пробатова Н.А., Тупицын Н.Н. и др. Лимфопролифера- тивные заболевания при болезни Шёгрена. Онкогематология 2007; 3 : 16-26.</p><p>Kassan S.S., Thomas T.L., Mout- sopoulos H.M., et al. Increased risk of lymphoma in sicca syndrome. Ann. Intern. Med.1978, 89: 888-892.</p><p>Voulgarelis М., Dafni U.G., Isenberg D. A., et al. Malignant lymphoma in primary Sj?gren's syndrome. A multicenter, retrospective, clinical study by the European Concerted Action on Sjgren's syndrome. Arthritis Rheum.1999; 42: 1765-1772.</p><p>Васильев В.И., Пробатова Н.А., Тупицин Н.Н. и др. MALT-лимфомы при болезни Шёгрена. Тер.Арх. 2006; 1, 45-49.</p><p>Harris N.L. Lymphoid proliferations of the salivary glands. Am.J.Clin.Pathol. 1999; 111 (Suppl. 1): 94-103.</p><p>Васильев В.И. Болезнь Шёгрена: клинико-лабораторные, иммуноморфо- логические проявления и прогноз. Дис. док.мед.наук - Москва, 2007.</p><p>Поддубная И.В. Лечение индолент- ных неходжкинских лимфом. Практическая Онкология. 2004; 5(3): 203-208.</p><p>Насонов Е.Л., Соловьев С.К. Перспективы применения моноклональных антител к В-лимфоцитам (Ритуксимаб) при воспалительных ревматических заболеваниях. Научно-практическая ревматология. 2007; 1:4-8.</p><p>Silverman G.J., Weisman S. Rituximab therapy and autoimmune disorders. Arthr.Rheum. 2003; 48(6): 1484-1491.</p><p>Cohen S.B. В-cell depletion for rheumatic disease: where are we? Med.Gen.Med. 2005 ; 7(2):1-13.</p><p>Родионова E.B., Васильев В.И., Прокопенко В.Д., Логвиненко О.А. Антигенпредставляющие клетки лимфо- гистиоцитарного инфильтрата при болезни Шёгрена. Научно-практическая ревматология. 2006; 3 : 16-20.</p><p>Harris N., Jaffe Е., Diebold J et al. The World Health Organization classification of neoplastic diseases of the hematopoetic and lymphoid tissues: report of the clinical advisory committee Meeting, Airlie House, Virginia, November, 1997. Ann.Oncol.1999; 10: 14191432.</p><p>Carbone P.P., Kaplan H.S., Musshoff K. et al. Report on the Committee on Hodgkin ’s Desease Studing Classification. Cancer Res.1971;31 : 1860-1861.</p><p>Shih W.J., Ghesani N., Hongming Z. et al. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of parotid gland in a patient with Sjogren's syndrome: before and after anti- CD20 antibody rituximab therapy. Clin. Nucl.Med.2002; 27: 142-143.</p><p>Somer B.G., Tsai D.E., Downs L. et.al. Improvement in Sjogren’s syndrome following therapy with rituximab for marginal zone lymphoma. Arthr.Rheum.2003; 49(3): 394-398.</p><p>Voulgarelis М., Giannouli S., Anagnostou D., Tzioufas A.G. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone [CHOP] for Sjogren's syndrome-associated В-cell aggressive non-Hodgkin’s lymphomas. Rheumatology [Oxford].2004; 43: 10501053.</p><p>Harner R.S.,Jockson L.W., Drabick J. J. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren’s syndrome. Rheumatology [Oxford],2004; 43 : 1309-1310.</p><p>Ramos-Casals М., Lopez-Guillermo A., Brito-Zeron P. et al. Treatment of B-cell lymphoma with rituximab in two patients with Sjogren's syndrome associated with hepatitis С virus infection. Lupus.2004; 13: 969-971.</p><p>Pijpe J., Imhoff G.W., Vissink A. et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann.Rhtum.Dis. 2005; 64:958-960.</p><p>Ring Т., Kallenbach М., Praetorius J. et al. Successful treatment of a patient with primary Sjogren's syndrome with Rituximab. Clin.Rheumatol.2006; 25 : 891-894.</p><p>Serror R., Sordet C., Guillevin L. Et al. Tolerance and efficacy of rituximab and changes in serum В cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann.Rheum.Dis. 2007; 66(3): 351-358.</p><p>Pijpe P., van Imhoff G.W., Spijkervet F.K., et al. Rituximab treatment in patients with Sjogren's syndrome: an open-label phase II study. Arthritis Rheum. 2005, 52 (9), 27402750.</p><p>Deyauchelle-Pensec V., Pennec Y, Morvan J. et al. Improvement of Sjogren's sendrome after two infusions of Rituximab (Anti-CD20). Arthr.Rheum.2007; 57(2) : 310317.</p><p>Cavalli F., Isaacson P.G., Gascoyne R.D., Zucca E. MALT Lymphas. Hematology. 2001; 241-258</p><p>Voulgarelis М., Giannjuli S., Tzioufas A. G., Moutsopoulos H.M. Long term remission of Sjogren’s syndrome associated aggressive В cell non-Hodgkin's lymphomas following combined В cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann. Rheum. Dis. 2006; 65 : 1033-1037.</p><p>Васильев В.И., Соловьев С.К., Логвиненко О.А., Насонов Е.Л. Успешное применение Ритуксимаба при "катастрофическом" течении системной красной волчанки с синдромом Шёгрена. Научнопрактическая ревматология.2006; 3 : 3337.</p><p>Gottenberg J.E., Guillevin L., Lam- botte О. Et al. Tolerance and shortterm efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum.Dis.2005; 64:913-920</p></div><br />